Dr Karen Bernstein joins Ovid and Vitae boards
pharmafile | October 1, 2015 | Appointment | Medical Communications, Sales and Marketing | Dr Karen Bernstein, Ovid Therapeutics, Vitae Pharmaceuticals
Ovid Therapeutics has announced the appointment of Karen Bernstein to the company’s Board of Directors.
Dr Bernstein says: “I have had the great pleasure to know the members of Ovid’s team over many years, and it is very exciting to see this group come together in forming a new company that I believe will make a major difference for patients with rare and orphan diseases of the brain. Recent scientific insights in CNS diseases open new avenues for the development of important new drugs. Ovid is uniquely suited to become a major player in this area. I very much look forward to being a part of the company’s progress and success.”
Dr Bernstein co-founded BioCentury in 1992 alongside President and CEO David Flores, with the goal of delivering the essential clinical, regulatory, and finance news shaping the biotechnology and pharmaceutical industries. She stepped down from her role as Editor-in-Chief in August, but will continue serving as BioCentury’s Chairman.
In addition to joining Ovid’s board of directors, Dr Bernstein has also joined the board of Vitae Pharmaceuticals. She currently serves as a trustee of the Keck Graduate Institute of the Applied Life Sciences and is a member of the Keck Graduate Institute School of Pharmacy’s board of advisors. Dr Bernstein earned a Ph.D. in political science from Stanford University and a B.A. in politics and history from Brandeis University.
Dr Jeremy Levin, CEO and chairman of Ovid, comments: “Karen has been instrumental in charting and interpreting the growth and evolution of the biotechnology industry. Her work and that of BioCentury is iconic. Her intellect, perspectives, and deep knowledge of the life science industry will be tremendous additions to our Board’s deliberations. We are privileged that she has joined Ovid’s board.”
Related Content
Vitae Pharma soars on positive mid-stage trial results for psoriasis drug
Shares in Vitae Pharmaceuticals (Nasdaq: VTAE) nearly doubled in pre-market trading Thursday after the company reported …
Boehringer and Vitae Pharma drug fails in mid-stage trial
A pipeline diabetes drug co-developed by Vitae Pharma and German giants Boehringer Ingelheim has failed …
